Arnold G. Vulto

Erasmus MC — Netherlands

Immunology and Microbiology · Life Sciences

57h-index12.5kcitations342works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Biosimilars and Bioanalytical Methods(103), Pharmaceutical Economics and Policy(99), Health Systems, Economic Evaluations, Quality of Life(79), Pharmaceutical studies and practices(55), Virus-based gene therapy research(22)

Publications339 total

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study
BioDrugs·2025Open Access
Barriers to adoption of biosimilar insulins in Europe: A mixed‐methods study
Diabetes Obesity and Metabolism·2025· 1 citedOpen Access
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients
The Lancet Respiratory Medicine·2025· 3 citedOpen Access
Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergence
Expert Opinion on Biological Therapy·2025· 7 cited
Drawing on collective action theory to foster sustainable biosimilar markets – insights from co-creation workshops with UK and Belgian stakeholders
Expert Opinion on Biological Therapy·2025
HPR64 Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Value in Health·2024Open Access
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Pharmaceutical Medicine·2024· 5 citedOpen Access
Review for "The economics of translating a biosimilar from lab to market in India"
2024
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain
BioDrugs·2024· 1 cited
Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment
Expert Review of Pharmacoeconomics & Outcomes Research·2024· 3 citedOpen Access
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective
Expert Review of Pharmacoeconomics & Outcomes Research·2024· 8 cited
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective
Figshare·2024Open Access
Biosimilars: Principles, Regulatory Framework, and Societal Aspects
Pharmaceutical biotechnology·2024
HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations
Value in Health·2023· 1 cited
Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease
Journal of Proteomics·2023· 8 citedOpen Access
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
Health Research Policy and Systems·2023· 6 citedOpen Access
Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
Frontiers in Pharmacology·2023· 28 citedOpen Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
page 1 of 17Next →

Frequent Co-authors

Steven Simoens(12), Isabelle Huys(9), Teun van Gelder(9), Albert Hofman(7), Loes E. Visser(7), Pieter Dylst(5), Bruno H. Stricker(5), Evelien Moorkens(4), Paul Declerck(4), Maarten J. J. E. Loonen(3), Arnold Reuser(3), Ans T. van der Ploeg(3), Brian Godman(3), Liese Barbier(3), Ron H. N. van Schaik(3), Ron A. A. Mathôt(3), H. van der Sijs(2), J. Aarts(2), Maarten J. ten Berg(2), C. B. H. W. Lamers(2)